Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

Author： Mulder C. J. J.   Hazel S. J. Van Den  

Publisher： Informa Healthcare

ISSN： 1466-1861

Source： Mediators of Inflammation, Vol.7, Iss.3, 1998-06, pp. : 135-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose‐Response Relationship of Physical Activity and Cardiovascular Disease Risk

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 46, Iss. 2, 1998-02 ,pp. : 238-240

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

By  

Nephron Clin Pract, Vol. 119, Iss. 2, 2011-06 ,pp. : c89-c96

Karger

Access to resources Recommend Favorite

Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease

By  

Transfusion Medicine and Hemotherapy, Vol. 35, Iss. 1, 2007-12 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease

By Rutgeerts P.  

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 137-140

Informa Healthcare

Access to resources Recommend Favorite

Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease

By Roberts Rebecca L   Gearry Richard B   Kennedy Martin A   Barclay Murray L  

Personalized Medicine, Vol. 5, Iss. 3, 2008-05 ,pp. : 233-248

Future Medicine

Access to resources Recommend Favorite